Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis

Cancer Research

Volumn 66, Issue 4, 2006, Pages 2305-2313

  Yan, Huajun ^a   Frost, Patrick ^a   Shi, Yijiang ^a   Hoang, Bao ^a   Sharma, Sanjai ^a   Fisher, Myrna ^a   Gera, Joseph ^a   Lichtenstein, Alan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAG 3 PROTEIN; DEXAMETHASONE; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 27; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN KINASE B; PROTEIN P53; RAF PROTEIN; RAPAMYCIN; STRESS ACTIVATED PROTEIN KINASE; TEMSIROLIMUS; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SENSITIZATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; CARRIER PROTEINS; CELL LINE, TUMOR; DEXAMETHASONE; DRUG SYNERGISM; FOCAL ADHESION KINASE 2; HUMANS; MAP KINASE KINASE 4; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RECEPTORS, GLUCOCORTICOID; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS;

EID: 33644516582     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2447     Document Type: Article

References (47)

1. Shi Y, Gera J, Hu L, et al. Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002;62:5027-34.
2. Hu L, Shi Y, Hsu J-h, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003;101:3126-35.
3. Stromberg T, Dimberg A, Hammarberg A, et al. Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone. Blood 2004;103:3138-47.
4. Huang S, Bjornsti M, Houghton P. Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther 2003;2:222-32.
5. Nelsen CJ, Rickheim DG, Tucker MM, Hansen LK, Albrecht JH. Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J Biol Chem 2003;278:3656-63.
6. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998;54:815-24.
7. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002;9:99-100.
8. Huang S, Shu L, Dilling MB, et al. Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21. Mol Cell 2003;11:1491-501.
9. Harada U, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 2001;98:9666-70.
10. Takano A, Usui I, Haruta T, et al. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular re-distribution of IRS-1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 2001;21:5050-62.
11. Ning YM, Sanchez ER. Potentiation of glucocorticoid receptor-mediated gene expression by the immunophilin ligands FK506 and rapamycin. J Biol Chem 1993;268:6073-6.
12. Davies TH, Ning YM, Sanchez ER. A new first step in activation of steroid receptors. J Biol Chem 2002;277:4597-600.
13. Zong Q, Schummer M, Hood L, Morris DR. Messenger RNA translation state: the second dimension of high throughput expression screening. Proc Natl Acad Sci U S A 1999;96:10632-6.
14. Frost P, Moatamed F, Hoang B, et al. In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model. Blood 2004;104:4181-7.
15. Greenstein S, Krett NL, Kurosawa Y, et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior and signaling of steroid-sensitive and - resistant MM cells. Exp Hematol 2003;4:271-8.
16. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
17. Mazers G-R, Portier M, Zhang X-G, et al. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992;7:1015-8.
18. Neshat MS, Mellinghoff I, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-9.
19. Gera J, Mellinghoff I, Shi Y, et al. AKT activity determines sensitivity to mTOR inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004;279:2737-46.
20. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of IL-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000;275:27845-50.
21. del Peso L, Gonzalez-Gracia M, Page C, Herrera R, Nunez G. IL-3-induced phosphorylation of BAD through the protein kinase AKT. Science 1997;278:687-9.
22. Chauhan D, Kharbanda S, Ogata A, et al. IL-6 inhibits Fas-induced apoptosis and stress activated protein kinase activation in multiple myeloma cells. Blood 1997;89:227-34.
23. Chauhan D, Pandey P, Ogata A, et al. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/ SAPkinase independent mechanism. Oncogene 1997;15:837-43.
24. Park WH, Seol JG, Kim ES, et al. Induction of apoptosis by vitamin D3 analogue EB1089 in NCI-H929 myeloma cells via activation of caspase 3 and p38 MAP kinase. Br J Haematol 2000;109:576-83.
25. Denny WB, Valentine DL, Reynolds PD, Smith DF, Scammell JG. Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor binding. Endocrinology 2004;141:4107-13.
26. Reynolds PD, Ruan Y, Smith DF, Scammell JG. Glucocorticoid resistance in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. J Clin Endocrinol Metab 2004;84:663-9.
27. Jefferies HBJ, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70S6K. EMBO J 1997;16:3693-704.
28. Mothe-Satney I, Yang D, Fadden P, Haystead TA, Lawrence JC. Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression. Mol Cell Biol 2000;20:3558-67.
29. Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC. CAIR-1/BAG-3 abrogates heat shock protein 70 chaperone complex-mediated protein degradation. J Biol Chem 2003;278:28490-500.
30. Romano MF, Festa M, Pagliuca G, et al. BAGS protein controls B-CLL apoptosis. Cell Death Differ 2003;10:383-5.
31. Deveraux QL, Reed JC. IAP family proteins: suppressors of apoptosis. Genes Dev 1999;13:239-52.
32. Yakoviev AG, Di Giovanni S, Wang G, Liu W, Stoica B, Faden AI. BOK and NOXA are essential mediators of p53-dependent apoptosis. J Biol Chem 2004;279:28367-74.
33. Chauhan D, Li G, Auclair D, et al. Identification of genes regulated by 2ME2 in multiple myeloma cells using oligonucleotide arrays. Blood 2003;101:3606-14.
34. Chauhan D, Li G, Hideshima T, et al. Hsp 27 inhibits release of mitochondrial Smac in multiple myeloma cells and confers dexamethasone resistance. Blood 2003;102:3379-86.
35. Li S, Sonenberg N, Gingras A-C, et al. Translational control of cell fate: availability of phosphorylation sites on translational represser 4E-BP1 governs its proapoptotic potency. Mol Cell Biol 2002;22:2853-61.
36. Polunovsky VA, Rosenwald IB, Tan A, et al. Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated myc. Mol Cell Biol 1996;16:6573-81.
37. Pollett JB, Trudell S, Stein D, Li ZH, Stewart AK. Overexpression of the myeloma-associated oncogene FGF receptor 3 confers dexamethasone resistance. Blood 2002;100:3819-21.
38. Ito H, Kamei K, Iwamato I, Inaguma Y, Kato K. Regulation of the levels of small heat shock proteins during differentiation of C2C12 cells. Exp Cell Res 2001;266:213-21.
39. Lowe S, Cepero E, Evan G. Intrinsic tumor suppression. Nat Insight 2004;432:307-15.
40. Shi Y, Sharma A, Wu H, Lichtenstein A, Gera J. Cyclin Da and c-myc IRES-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK and ERK-dependent pathway. J Biol Chem 2005;280:10964-73.
41. Mitchell SA, Spriggs KA, Coldwell MJ, Jackson RJ, Willis AE. The APAF-1 IRES attains the correct structural conformation for function via interactions with PTB and unr. Mol Cell 2003;11:757-71.
42. Henis-Korenblit S, Strumpf NL, Goldstaub D, Kimchi A. A novel form of DAP5 protein accumulates in apoptotic cells as a result of caspase cleavage and IRES-mediated translation. Mol Cell Biol 2000;20:496-506.
43. Holcik M, Gordon BW, Korneluk RG. The IRES-mediated translation of antiapoptotic XIAP is modulated by the heterogenous nuclear ribonucleoproteins C1 and C2. Mol Cell Biol 2003;23:280-8.
44. Joshi-Barve S, DeBenedetti A, Rhoads RE. Preferential translation of heat shock mRNAs in HeLa cells deficient in protein synthesis initiation factors eIF-4E and eIF-4γ. J Biol Chem 1992;267:21038-43.
45. Yamagiwa Y, Marienfeld C, Meng F, Holcik M, Patel T. Translational regulation of X-linked inhibitor of apoptosis protein by IL-6: novel mechanism of tumor cell survival. Cancer Res 2004;64:1293-8.
46. Hsu J-h, Shi Y, Krajewski S, et al. The AKT kinase is activated in multiple myeloma tumor cells. Blood 2001;98:2853-5.
47. Wendel H-G, de Stanchina E, Fridman JS, et al. Survival signaling by AKT and eIF4E in oncogenesis and cancer therapy. Nature 2004;428:332-7.